查詢結果分析
相關文獻
- Biochemical Markers for Assessment of Bone Metastases in Patients with Breast Cancer
- Evaluation of Serum CA27.29, CA15-3 and Cea in Patients with Breast Cancer
- Serum-Soluble Interleukin-2 Receptor Concentrations in Patients with Breast Cancer: A Preliminary Report
- Comparison of Serum Ca15-3 and CEA in Breast Cancer
- 乳癌病人血清出現特異的肌酸激酶 (預報)
- Fever, Rash and Acute Inflammatory Polyarthritis in a Breast Cancer Patient after Trastuzumab Treatment: a Case Report
- Differential Profiles of Circulating Cytokines, Leptin, and Nitric Oxide in Patients with Breast and Colorectal Cancers
- 乳癌術後之上肢問題的醫學新知與物理治療
- The Effects of Pesticides Chlordane, Dieldrin and Endosulfan on the Growth of Human Breast Cancer Cell Lines MCF-7 and SK-BR-3
- Clinical Characteristics and Coronary Risk Factors of Patients with Low Concentrations of Serum Low-Density Lipoprotein Cholesterol and Total Cholesterol
頁籤選單縮合
題 名 | Evaluation of Serum CA27.29, CA15-3 and Cea in Patients with Breast Cancer=乳癌患者血清中CA27.29,CA15-3及CEA之比較 |
---|---|
作 者 | 侯明鋒; 陳宜伶; 曾翠芬; 林秋美; 陳美杏; 黃哲人; 黃裕勝; 謝建勳; 黃宗人; 鍾相彬; 黃英峰; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 15:9 1999.09[民88.09] |
頁 次 | 頁520-528 |
分類號 | 416.226 |
關鍵詞 | 乳癌; 血清; Breast cancer; CA27.29; CA15-3; |
語 文 | 英文(English) |
中文摘要 | 對於乳癌患者血清中的MUC-1基因產物所生的eA27.29抗原所發展的單株抗體BR27.29,我們利用放射免疫法來測定其抗原,並與傳統血清腫瘤標記CEA及CA15-3來比較CA27.29在乳癌患者的應用。在112例健康女性的血清發現CA27.29的平均值為12.4±4.1單位/毫升,其正常值上限為25單位/毫升。145例乳癌患者血清中CA27.29上升者為37例 (敏感度25.5%),CA15-3上升者則為35例(敏感度24.1%),CEA上升者27例 (敏感度18.6%),在110例乳癌未轉移組,其CA27.29的敏感度為6.4%,CA15-3敏感度為5.5%,而CEA敏感度為4.5%,平均值CA27.29是10.2 ± 9.2單位/毫升,CA15-3為14.1 ± 5.6單位/毫升,CEA為1.7±亳微克/亳升 (p>0.05)。而在35例 (24.2%) 乳癌轉移者,其CA27.29敏感度則為85.7%,CA15-3敏感度82.2% (p>0.05),而CEA敏感度為62.8% (p<0.05),其平均值則CA27.29為152.6 ± 131.6單位/毫升,CA15-3為123.1 ± 107.6單位/毫升,CEA則為21.8 ± 36.9亳微克/毫升。結果顯示,CA27.29並不是乳癌的篩檢工具,但它在乳癌轉移的敏感度上,較CEA為佳 (p<0.05),而與CA15-3類似,亦可做為乳癌轉移追蹤及治療反應的參考。 |
英文摘要 | The Truquant BR radio-immunoassay (RIA) using monoclonal antibody BR 27.29 to recognize a peptide sequence on the MUC-1 gene product for quantification of the CA27.29 antigen in serum was used in this report to evaluate in 145 patients with breast cancer and compared the other conventional serum markers such as CA15-3 and CEA. The upper limit of normal (25 u/ml) was determined from CA27.29 values 12.4 ± 4.1 u/ml (mean ± 3 S.D.) for 112 female subjects apparently free of disease. The CA15-3 levels above 25 u/ml and CEA levels above 5 ng/ml were considered positive values. Thirty-seven cases of 145 patients studied had elevated CA 27.29 levels (sensitivity: 25.5%), 35 of 145 had positive CA15-3 levels (sensitivity 24.1%) and 27 of 145 patients had positive CEA levels (sensitivity: 18.6%) (p<0.05). One hundred and ten cases of the breast cancer patients (75.8%) did not have metastatic disease. In this group CA 27.29 sensitivity was 6.4%, while CA15-3 sensitivity was 5.5% and CEA sensitivity was 4.5% (p>0.05). Mean values were 10.2 ± 9.2 u/ml for CA 27.29, 14.1 ± 5.6 u/ml for CA15-3 and 1.7 ± 1.5 ng/ml for CEA. Thirty-five patients (24.2%) had metastatic disease. In this group CA 27.29 sensitivity was 85.7%, CA15-3 sensitivity was 82.8% and CEA sensitivity was 62.8% (p<0.05). Mean values for CA27.29 was 152.6 ±131.6 u/ml, CA15-3 was 123.1 ± 107.6 u/ml and 21.8 ± 36.9 ng/ml of CEA. With regard to the correlation of three tumor markers with clinical stages, patients had significantly higher levels of CA27.29 than CEA, but they were similar to CA15-3 in metastatic breast cancer. These results suggest CA27.29 to be more sensitive and specific than CEA, but that it is similar to CA15-3 for metastatic breast cancer detection and monitoring. |
本系統中英文摘要資訊取自各篇刊載內容。